GenoMed's Dr. David Moskowitz Featured on Wall Street Reporter; Says Genomics-Based Preventive Medicine Best Cure for Healthcare Crisis
FOR IMMEDIATE RELEASE Contact:
Dr. David Moskowitz GenoMed, Inc. tel. 314-652-0500
June 23, 2004--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that its Chairman and CEO, Dr. David Moskowitz, is featured in Wall Street Reporter Magazine ( wallstreetreporter.com ) discussing how preventive molecular medicine as GenoMed practices it can significantly lower healthcare costs.
GenoMed has aligned its business model with optimizing public health. The Company's goal is to find the least expensive, fastest, and safest way to improve patient outcomes. The Company has already accomplished this for diabetes, hypertension, and emphysema, which affect over 83 million Americans. This summer GenoMed will conduct a free national trial for West Nile virus using already existing, FDA-approved drugs.
GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's). Rather than waiting for bureaucratic health plans to embrace its Next Generation Disease Management(tm), GenoMed is now encouraging patients who control their own Health Savings Account to sign up themselves for GenoMed's modestly priced services.
About GenoMed
GenoMed's goal is to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" link at genomedics.com. |
